Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Keros Therapeutics ( (KROS) ) just unveiled an announcement.
On June 4, 2025, Keros Therapeutics held its Annual Meeting of Stockholders, where stockholders voted on three proposals, including the election of directors, ratification of Deloitte & Touche LLP as the independent auditor, and approval of executive compensation. Subsequently, on June 9, 2025, Keros announced the conclusion of its strategic alternatives review, deciding to return $375 million in excess capital to stockholders. This decision reflects a thorough review of capital requirements and stockholder feedback, while the company continues to focus on developing KER-065 for neuromuscular diseases.
The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The overall stock score of 50.9 reflects significant financial challenges, including unprofitability and reliance on external financing, balanced by strong technical momentum. The recent negative corporate event involving workforce reduction indicates strategic realignment but also potential instability. Valuation remains challenging due to negative earnings.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat disorders linked to dysfunctional signaling of the TGF-ß family of proteins. The company is a leader in understanding the role of these proteins, which regulate the growth, repair, and maintenance of various tissues. Keros’ lead product candidate, KER-065, is being developed for neuromuscular diseases, particularly Duchenne muscular dystrophy, while its most advanced candidate, elritercept (KER-050), targets cytopenias in myelodysplastic syndrome and myelofibrosis patients.
Average Trading Volume: 957,445
Technical Sentiment Signal: Sell
Current Market Cap: $610.9M
For detailed information about KROS stock, go to TipRanks’ Stock Analysis page.